
Claims:

1. A crystalline compound of Formula (I):




(I)

that produces a powder X-ray diffraction spectrum comprising peaks at diffraction angles (2Θ±0.2º) of 18.5 and 19.3.

2. The crystalline compound of claim 1, further comprising peaks at diffraction angles (2Θ±0.2º) of 21.1 and 22.2.

3. The crystalline compound of claim 1 or 2, further comprising peaks at diffraction angles (2Θ±0.2º) of 7.4, 9.6, 14.7, and 16.7.

4. A crystalline compound of Formula (I):




(I)

wherein at least ~~about~~ 90% by wt. of the total amount of the crystalline compound of Formula (I) is crystalline Form A, which produces a powder X-ray diffraction spectrum comprising at least three peaks at diffraction angles (2Θ±0.2º) selected from 7.4, 9.6, 14.7, 16.7, 17.1, 18.5, 19.3, 21.1, and 22.2.

5. The crystalline compound of any one of claims 1 to 4, wherein the crystalline compound has a particle size D_{90} of 15 µm.

6. The crystalline compound of any one of claims 1 to 4, wherein the crystalline compound has a particle size D_{90} of 8 µm.


7. A crystalline compound of Formula (I):



(I)

that produces a powder X-ray diffraction spectrum as shown in FIG. 3A.

8. A crystalline compound of Formula (I):



(I)

that has a differential scanning calorimetry (DSC) thermogram with an endothermic event having a peak temperature at ~~about~~ 241°C.

9. A pharmaceutical composition comprising a crystalline compound according to any one of claims 1 to 8, and at least one pharmaceutically acceptable excipient.

10. A dosage unit comprising from ~~about~~ 0.16 mg to ~~about~~ 8.0 mg of a crystalline compound according to any one of claims 1 to 8.


11. The dosage unit of claim 10, wherein the dosage unit is a solid oral dosage form.

12. The dosage unit of claim 11, wherein the solid oral dosage for is a tablet or capsule.

13. The dosage unit of any one of claims 10 to 12, wherein the dosage unit comprises from ~~about~~ 0.5 mg to ~~about~~ 6.0 mg of the crystalline compound of Formula (I).

14. The dosage unit of any one of claim 10 to 12, wherein the dosage unit comprises from ~~about~~ 0.5 mg to ~~about~~ 3.0 mg of the crystalline compound of Formula (I).

15. A process for producing a crystalline compound of Formula (I):



(I)

in crystalline Form A comprising the steps:

dissolving a compound of Formula (I) in formic acid to form a solution;

diluting the solution with ethyl acetate solvent to form a diluted solution;

forming a slurry in the diluted solution; and

filtering the slurry to isolate the crystalline Form A of Formula (I) form, which produces a powder X-ray diffraction spectrum comprising at least three peaks at

diffraction angles (degrees 2Θ±0.2º) selected from 7.4, 9.6, 14.7, 16.7, 17.1, 18.5, 19.3, 21.1, and 22.2.

16. The process of claim 15, further comprising the step of adding *p*-toluenesulfonic acid to the solution.

17. Use of the crystalline compound according to any one of claims 1 to 8 in the manufacture of a medicament for the treatment, prevention or management of a sleep disorder.

18. The use according to claim 17, wherein the sleep disorder is selected from the group consisting of insomnia; an alcohol-induced sleep disorder; insomnia in alcohol use disorder; a sleep disturbance associated with alcohol cessation; hypersomnia; circadian rhythm sleep-wake disorder; or any combination thereof.

19. The crystalline compound according to any one of claims 1 to 8 for use in the treatment, prevention or management of a sleep disorder.

20. The crystalline compound for use according to claim 19, wherein the sleep disorder is selected from the group consisting of insomnia; an alcohol-induced sleep disorder; insomnia in alcohol use disorder; a sleep disturbance associated with alcohol cessation; hypersomnia; circadian rhythm sleep-wake disorder; or any combination thereof.